PET scan with [11C]erlotinib may provide noninvasive method to identify...
A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to...
View ArticleEURTAC Phase III study: Erlotinib nearly doubles progression-free survival...
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to...
View ArticleErlotinib dose-adjusted for smoking status effective as first treatment for...
Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the...
View ArticleNew analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations,...
View ArticleThe right combination: Overcoming drug resistance in cancer
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however,...
View ArticleAdding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic...
The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to...
View ArticleScientists looking for second-line defense for patients with NSCLC
DENVER- In lung cancer, patients who benefit from drugs like erlotinib will inevitably develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists...
View ArticleScientists reverse Alzheimer's-like memory loss in animal models by blocking...
A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic...
View ArticleStudy says VeriStrat predicts response but not survival benefit from erlotinib
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response...
View ArticlePainless skin rash predicts survival benefit from latest lung cancer drug,...
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2...
View ArticleStudy shows different approach after progression in non-small cell lung...
Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor...
View ArticleLung cancer patients with pockets of resistance prolong disease control by...
The central skill of cancer is its ability to mutate – that's how it became cancerous in the first place. Once it's started down that path, it's not so difficult for a cancer cell to mutate again and...
View ArticleNew drug combination could prevent head and neck cancer in high-risk patients
(Medical Xpress)—A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of...
View ArticleComparing combination therapies for advanced head and neck cancer shows no...
Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50...
View ArticleA hijacking of healthy cellular circuits
Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth...
View ArticleNew treatment holds promise for resistant lung cancer
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the...
View ArticleGene signature can predict who will survive chemotherapy
An eight gene 'signature' can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central's open access journal BMC Medicine.
View ArticleTumors with ALK rearrangements can harbor more mutations
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown,...
View ArticleEORTC intergroup trial opens for patients with resected head of pancreas...
Surgical resection is considered a potentially curative treatment for pancreatic adenocarcinoma, however, the five year survival rate of patients receiving this treatment is less than 20 percent....
View ArticleStudy predicts cancer drug responsiveness in human tumors
It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex...
View ArticleMolecular marker predicts patients most likely to benefit longest from two...
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs...
View ArticlePhase II trial of efatutazone shows challenge of matching treatment to...
Work at the University of Colorado Cancer Center led to phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer. Results are reported today at the American...
View ArticleIncreased overall survival for advanced stage nsclc patients associated with...
A 10-year population-based study shows that increased availability of better systemic chemo- and targeted-therapies for patients with advanced non-small cell lung cancer (NSCLC) coincides with...
View ArticleStudy may explain why targeted drug doesn't benefit patients with early-stage...
The drug erlotinib is highly effective in treating advanced-stage lung cancer patients whose tumors have a particular gene change, but when the same drug is used for patients with early-stage tumors...
View ArticleDual therapy's 1-2 punch knocks out drug-resistant lung cancer
Capitalizing on a rare opportunity to thoroughly analyze a tumor from a lung cancer patient who had developed resistance to targeted drug treatment, UC San Francisco scientists identified a biological...
View ArticleFirst precision medicine trial in cancer prevention identifies...
A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss...
View ArticleCola intake increases exposure of erlotinib
(HealthDay)—Cola intake leads to a clinically relevant and statistically significant increase in the bioavailability of erlotinib during esomeprazole treatment, according to a study published online...
View ArticleChemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with...
View ArticleTargeted therapies beneficial in KRAS-mutated NSCLC
(HealthDay)—Targeted therapies that do not contain erlotinib can be beneficial for patients with KRAS-mutated (KRAS mut+) advanced non-small-cell lung cancer (NSCLC), according to a study published...
View ArticleErlotinib overdose tied to conjunctivitis
(HealthDay)—Overdosing of erlotinib may be associated with rapid onset of conjunctivitis, according to a case report published online Oct. 25 in the Journal of Clinical Pharmacy and Therapeutics.
View Article
More Pages to Explore .....